Key clinical point: Docetaxel transiently decreased health-related quality of life (HRQoL) during chemotherapy in patients with intermediate-/high-risk localized prostate cancer, but the decline is temporary and recovers at 1 year. The decline was clinically meaningful in functional and physical domains.
Major finding: At the end of treatment (24 weeks), the HRQoL significantly declined in the docetaxel vs surveillance group (mean difference [MD], ─7.1 points; P < .0001). At 1 year, the HRQoL was similar between the 2 groups ( P = .344). A clinically significant decline in HRQoL scores during treatment with docetaxel was reported in functional (MD, –2.43 points; P < .0001) and physical domains (MD, –2.89 points; P < .0001).
Study details: Post hoc analysis of a randomized, phase 3 SPCG-13 study including 376 patients with intermediate-/high-risk localized prostate cancer following radiotherapy were randomly assigned to docetaxel or surveillance.
Disclosures: This work was supported by Tampere University Hospital. The authors received advisory/speaker fees from various sources.
Source: Lehtonen M et al. Anticancer Res. 2021 Dec 29. doi: 10.21873/anticanres.15460 .